Small study compares two ways to take experimental esophagitis drug

NCT ID NCT07093008

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested two different forms of the experimental drug AQ280 in 9 healthy adults. The goal was to see how well the body absorbs the drug when given as a capsule versus a tablet that dissolves in water. The results will help researchers decide which form to use in future studies for eosinophilic esophagitis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AQ280

What this could lead to

If successful, this study could help determine the best way to give AQ280 to patients with eosinophilic esophagitis in future trials.

What could go wrong

This is a very early, small study in healthy people, not patients. It only looks at how the drug is absorbed, not whether it works for the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic esophagitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Research Site

    Madison, Wisconsin, 53704, United States